- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
CORONA Remedies Limited has presented to analysts and investors. The presentation covers financial and operational performance for Q4 and FY26, highlighting strong revenue growth driven by brand strength and strategic acquisitions. Key financial metrics include revenue, EBITDA, and PAT margins, with significant year-on-year increases. Management emphasized a focused brand-building approach and highlighted strategic growth initiatives, including expanding therapeutic areas and product portfolio management. The company expressed a positive outlook, leveraging its execution capabilities and strategic advantages.